What is the longest interval that you have been able to stretch a biologic before losing efficacy?   

Naturally, this is subject a number of factors and is likely patient-dependent. We also recognize that the way clinical trials have been designed lead to shared intervals (ex: tralokinumab and dupilumab sharing q2w intervals).

Please state the biologic and disease state (ex: atopic dermatitis, psoriasis, etc.).